Randomized Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in KRAS-WT Tumors

Patient who's suffering from colorectal cancer with resectable metastases are invited to participate at this study. In this type of cancer (KRAS Wild Type) and as often it is realized actually the treatment will be a chemotherapy (FOLFOX or FOLFIRI) combining with Cetuximab, before the resection of they metastases. The goal of the study is to demonstrate the superiority of combining FOLFIRI + Cetuximab comparing FOLFOX + Cetuximab for the pathological response on the resected metastases. Actually the pathological response of the metastases after chemotherapy is a validated prognostic tool. All the chemotherapy treatments are proved they efficacy in the field of metastatic colorectal cancer, and they are reimbursed in this indication. The study wants to demonstrate the best association with Cetuximab in the way of pathological response.